---
schema_version: "secwatch.filing_event.v1"
accession: "0001823239-22-000015"
form_type: "8-K"
ticker: "MRVI"
cik: "0001823239"
company_name: "MARAVAI LIFESCIENCES HOLDINGS, INC."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:57:56.032454+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Maravai Q1 revenue $244.3M (+65% YoY); net income $146.9M; raises FY22 guidance

## Summary
- Record Q1 revenue $244.3M, up 65% YoY; Nucleic Acid Production $223.7M (+80%).
- Net income $146.9M (+95% YoY); Adjusted EBITDA $187.0M (77% margin).
- Nucleic Acid Production base business (ex-COVID CleanCap) revenue grew 55% YoY.
- Full-year 2022 revenue guidance reaffirmed; Adjusted EBITDA and EPS guidance raised.
- Deborah Barbara appointed Vice President, Business Development and Strategy.

## SEC filing metadata
- accession: 0001823239-22-000015
- form_type: 8-K
- ticker: MRVI
- cik: 0001823239
- company_name: MARAVAI LIFESCIENCES HOLDINGS, INC.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1823239/000182323922000015/0001823239-22-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1823239/000182323922000015/mrvi-20220505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001823239-22-000015
- JSON: https://secwatch.observer/filing/0001823239-22-000015.json
- Plain text: https://secwatch.observer/filing/0001823239-22-000015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.